. 2012 Aug 8;103(9):1640–1650. doi: 10.1111/j.1349-7006.2012.02367.x

Table 1.

Statistical analysis of the differential upregulation of PRMT5 in various primary and metastatic cancers using NCBI GEO datasets

Disease	Probeset of PRMT5	Variable	Sample number	P‐value	GSE Acc#	References
Lung cancer	217786_at	Normal	5	0.004*	GSE3268	44
Lung cancer	217786_at	Disease	5	0.004*	GSE3268	44
Gastric cancer	AF015913_at	Normal	8	0.001*	GSE2685	45
Gastric cancer	AF015913_at	Disease	22	0.001*	GSE2685	45
Bladder cancer	217786_at	Normal	9	0.000*	GSE3167	46
Bladder cancer	217786_at	Transitional cell carcinoma with CIS	13	0.000*	GSE3167	46
Bladder cancer	217786_at	Normal	9	0.000*	GSE3167	46
Bladder cancer	217786_at	Transitional cell carcinoma without CIS	15	0.000*	GSE3167	46
Colon	217786_at	Primary	3	0.006*	GSE1323	47
Colon	217786_at	Metastatic	3	0.006*	GSE1323	47

*Indicates the static significance of PRMT5 expression level between normal and cancerous tissues.